Literature DB >> 18715271

Frontotemporal lobar degeneration with ubiquitinated tau-negative inclusions and additional alpha-synuclein pathology but also unusual cerebellar ubiquitinated p62-positive, TDP-43-negative inclusions.

Andrew King1, Safa Al-Sarraj, Christopher Shaw.   

Abstract

Mutations in the progranulin (PGRN) gene on chromosome 17 have been shown to be responsible for one non-tauopathy subtype of familial frontotemporal lobar degeneration - frontotemporal lobar degeneration with ubiquitinated, tau-negative inclusions (FTLD-U). Such cases have pathological similarities to sporadic cases with neuronal inclusions positive for ubiquitin, the ubiquitin binding protein, p62 and the newly recognised protein TDP-43 but negative for hyperphosphorylated (HP) tau. There has been a recent report on two families with a novel progranulin mutation where the neuropathology showed not only TDP-43 neuronal positivity but separate tau and/or alpha-synuclein pathology. We describe an unusual case with some family history but no mutation in the progranulin gene. The pathological features were typical for FTLD-U but with additional significant alpha-synuclein pathology, and unusual ubiquitin-positive, p62-positive, TDP-43-negative inclusions in the cerebellum. This case may represent a further pathological phenotype for familial FTLD-U. It also highlights the need for further investigations on the ubiquitin binding protein p62 as a marker in FTLD-U. It is certainly possible that the presence or absence of these ubiquitinated p62-positive yet TDP-43-negative cerebellar inclusions may act as a useful correlative factor in the future.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18715271     DOI: 10.1111/j.1440-1789.2008.00966.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  8 in total

Review 1.  Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants.

Authors:  Shahram Saberi; Jennifer E Stauffer; Derek J Schulte; John Ravits
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

2.  Dynamic expression of the mouse orthologue of the human amyotropic lateral sclerosis associated gene C9orf72 during central nervous system development and neuronal differentiation.

Authors:  Ross Ferguson; Eleni Serafeimidou-Pouliou; Vasanta Subramanian
Journal:  J Anat       Date:  2016-08-01       Impact factor: 2.610

3.  Frontotemporal lobar degeneration with TDP-43 proteinopathy and chromosome 9p repeat expansion in C9ORF72: clinicopathologic correlation.

Authors:  Eileen H Bigio; Sandra Weintraub; Rosa Rademakers; Matt Baker; Saman S Ahmadian; Alfred Rademaker; Bing Bing Weitner; Qinwen Mao; Kyung-Hwa Lee; Manjari Mishra; Rakhee A Ganti; M-Marsel Mesulam
Journal:  Neuropathology       Date:  2012-06-18       Impact factor: 1.906

4.  C9ORF72, the new gene on the block, causes C9FTD/ALS: new insights provided by neuropathology.

Authors:  Eileen H Bigio
Journal:  Acta Neuropathol       Date:  2011-12       Impact factor: 17.088

Review 5.  TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration.

Authors:  Clotilde Lagier-Tourenne; Magdalini Polymenidou; Don W Cleveland
Journal:  Hum Mol Genet       Date:  2010-04-15       Impact factor: 6.150

6.  Macroautophagy is defective in mucolipin-1-deficient mouse neurons.

Authors:  Cyntia Curcio-Morelli; Florie A Charles; Matthew C Micsenyi; Yi Cao; Bhuvarahamurthy Venugopal; Marsha F Browning; Kostantin Dobrenis; Susan L Cotman; Steven U Walkley; Susan A Slaugenhaupt
Journal:  Neurobiol Dis       Date:  2010-06-28       Impact factor: 5.996

7.  Neuropathology of the Mcoln1(-/-) knockout mouse model of mucolipidosis type IV.

Authors:  Matthew C Micsenyi; Kostantin Dobrenis; Gloria Stephney; James Pickel; Marie T Vanier; Susan A Slaugenhaupt; Steven U Walkley
Journal:  J Neuropathol Exp Neurol       Date:  2009-02       Impact factor: 3.685

Review 8.  The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis.

Authors:  Johnathan Cooper-Knock; Janine Kirby; Robin Highley; Pamela J Shaw
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.